ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RPTX Repare Therapeutics Inc

3.20
0.05 (1.59%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 71,408
Bid Price 3.11
Ask Price 3.54
News (1)
Day High 3.25

Low
2.98

52 Week Range

High
13.85

Day Low 3.11
Company Name Stock Ticker Symbol Market Type
Repare Therapeutics Inc RPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 1.59% 3.20 16:31:36
Open Price Low Price High Price Close Price Prev Close
3.15 3.11 3.25 3.20 3.15
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
927 71,408 $ 3.18 $ 227,366 - 2.98 - 13.85
Last Trade Time Type Quantity Stock Price Currency
16:00:06 85 $ 3.20 USD

Repare Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
134.98M 42.18M - 51.13M -93.8M -2.22 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Repare Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RPTX Message Board. Create One! See More Posts on RPTX Message Board See More Message Board Posts

Historical RPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.023.432.983.24131,5370.185.96%
1 Month4.704.772.983.68113,198-1.50-31.91%
3 Months6.918.492.985.78125,699-3.71-53.69%
6 Months3.838.492.985.47242,169-0.63-16.45%
1 Year9.2613.852.986.78186,164-6.06-65.44%
3 Years32.0835.752.9813.98229,880-28.88-90.02%
5 Years32.0546.442.9816.41208,652-28.85-90.02%

Repare Therapeutics Description

Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Your Recent History

Delayed Upgrade Clock